Houte Hans Van Sells 4,761 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 4,761 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):

• On Thursday, July 30th, Houte Hans Van sold 2,845 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total transaction of $66,516.10.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $24.69 on Wednesday. Nurix Therapeutics, Inc. has a fifty-two week low of $8.19 and a fifty-two week high of $25.08. The company has a market capitalization of $2.56 billion, a PE ratio of -7.16 and a beta of 1.79. The stock has a fifty day moving average of $20.80 and a two-hundred day moving average of $17.92.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The business had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NRIX. General Atlantic L.P. purchased a new stake in Nurix Therapeutics during the fourth quarter valued at about $92,899,000. Morgan Stanley raised its holdings in shares of Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock worth $92,594,000 after purchasing an additional 2,620,323 shares during the period. Rubric Capital Management LP purchased a new position in shares of Nurix Therapeutics in the 4th quarter worth about $46,930,000. Braidwell LP acquired a new position in shares of Nurix Therapeutics in the 4th quarter valued at about $41,428,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Nurix Therapeutics by 195.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company’s stock valued at $61,622,000 after purchasing an additional 2,149,268 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NRIX. UBS Group raised their price target on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. HC Wainwright increased their price objective on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Jefferies Financial Group raised their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Morgan Stanley boosted their target price on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 price target on shares of Nurix Therapeutics in a research report on Tuesday. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.00.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.